Nivolumab Combined With SOX Used in the Perioperative Treatment
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX
(oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal
junction adenocarcinoma;